KIT and gastrointestinal stromal tumor: For example, in addition to Bcr-Abl, imatinib is able to inhibit c-Kit and PDGFR kinases, which also makes it possible to use this substance for the treatment of gastrointestinal stromal tumors (GIST) [10].